Risk of hepatitis B virus reactivation following ruxolitinib treatment in patients with myeloproliferative neoplasms

References

• Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol: Offic J Amer Soc Clin Oncol. 2014 Nov 20;32(33):3736–3743.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol: Offic J Amer Soc Clin Oncol. 2009 Feb 1;27(4):605–611.
   PubMed Web of Science ®Google Scholar
• Matsue K, Kimura S, Takanashi Y, et al. Reactivation of hepatitis B virus after rituximab-containing treatment in patients with CD20-positive B-cell lymphoma. Cancer. 2010 Oct 15;116(20):4769–4776.
   PubMed Web of Science ®Google Scholar
• Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association i. American Gastroenterological Association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):215–219.; quiz e16-7.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.. Leukemia. 2016 Aug;30(8):1701–1707.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Gotlib J, Gupta V, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol: OfficJ Amer Soc Clin Oncol. 2013 Apr 1;31(10):1285–1292.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Vannucchi AM, Griesshammer M, et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016 Jul;101(7):821–829.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017 Jul;96(7):1113–1120.
   PubMed Web of Science ®Google Scholar
• Gill H, Leung GMK, Seto WK, et al. Risk of viral reactivation in patients with occult hepatitis B virus infection during ruxolitinib treatment. Ann Hematol. 2019 Jan;98(1):215–218.
   PubMed Web of Science ®Google Scholar
• Eyal O, Flaschner M, Ben Yehuda A, et al. Varicella-zoster virus meningoencephalitis in a patient treated with ruxolitinib. Am J Hematol. 2017 May;92(5):E74–EE5.
   PubMed Web of Science ®Google Scholar
• Perricone G, Vinci M, Pungolino E. Occult hepatitis B infection reactivation after ruxolitinib therapy . Dig Liver Dis. 2017 Jun;49(6):719.
   PubMedGoogle Scholar
• Ballesta B, Gonzalez H, Martin V, et al. Fatal ruxolitinib-related JC virus meningitis. J Neurovirol. 2017 Oct;23(5):783–785.
   PubMed Web of Science ®Google Scholar
• Dioverti MV, Abu Saleh OM, Tande AJ. Infectious complications in patients on treatment with ruxolitinib: case report and review of the literature. Infect Dis. 2018 May;50(5):381–387.
   PubMed Web of Science ®Google Scholar
• Reoma LB, Trindade CJ, Monaco MC, et al. Fatal encephalopathy with wild-type JC virus and ruxolitinib therapy. Ann Neurol. 2019 Dec;86(6):878–884.
   PubMed Web of Science ®Google Scholar
• Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014 Jan;28(1):225–227.
   PubMed Web of Science ®Google Scholar
• Shen CH, Hwang CE, Chen YY, et al. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol. 2014 Jun;93(6):1075–1076.
   PubMed Web of Science ®Google Scholar
• Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. report of a prospective study. Gastroenterology. 1991 Jan;100(1):182–188.
   PubMed Web of Science ®Google Scholar
• Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J. Clin Oncol: Offic J Amer Soc Clin Oncol. 2004 Mar 1;22(5):927–934.
   PubMed Web of Science ®Google Scholar
• Paul S, Saxena A, Terrin N, et al. Hepatitis B virus reactivation and prophylaxis during solid tumor chemotherapy: A systematic Review and meta-analysis. Ann Intern Med. 2016 Jan 5;164(1):30–40.
   PubMed Web of Science ®Google Scholar
• Huang YH, Hsiao LT, Hong YC, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol: Offic J Amer Soc Clin Oncol. 2013 Aug 1;31(22):2765–2772.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1;366(9):799–807.
   PubMed Web of Science ®Google Scholar
• Hammond SP, Chen K, Pandit A, et al. Risk of hepatitis B virus reactivation in patients treated with ibrutinib. Blood. 2018 Apr 26;131(17):1987–1989.
   PubMed Web of Science ®Google Scholar
• Duan M, Zhou D. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone. Hematology. 2019 Dec;24(1):516–520.
   PubMed Web of Science ®Google Scholar
• Tur-Kaspa R, Burk RD, Shaul Y, et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA. 1986 Mar;83(6):1627–1631.
   PubMed Web of Science ®Google Scholar
• Chou CK, Wang LH, Lin HM, et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology. 1992 Jul;16(1):13–18.
   PubMed Web of Science ®Google Scholar
• Carson P, Hong CJ, Otero-Vinas M, et al. Liver enzymes and lipid levels in patients with lipodermatosclerosis and venous ulcers treated with a prototypic anabolic steroid (stanozolol): a prospective, randomized, double-blinded, placebo-controlled trial. Int J Low Extrem Wounds. 2015 Mar;14(1):11–18.
   PubMed Web of Science ®Google Scholar